Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All lactoferrin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchLactoferrinLactoferrin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19

Mirabelli et al., Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118
Aug 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
In Vitro study testing 1,425 compounds for SARS-CoV-2 antiviral activity, identifying 17 dose-responsive compounds with IC50 values <1μM. Lactoferrin inhibited SARS-CoV-2 in the nanomolar range in all cell models with multiple modes of action.
Mirabelli et al., 19 Aug 2021, peer-reviewed, 23 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperLactoferrinAll
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19
Carmen Mirabelli, Jesse W Wotring, Charles J Zhang, Sean M Mccarty, Reid Fursmidt, Carla D Pretto, Yuanyuan Qiao, Yuping Zhang, Tristan Frum, Namrata S Kadambi, Anya T Amin, Teresa R O'meara, Jason R Spence, Jessie Huang, Konstantinos D Alysandratos, Darrell N Kotton, Samuel K Handelman, Christiane E Wobus, Kevin J Weatherwax, George A Mashour, Matthew J O'meara, Arul M Chinnaiyan, Jonathan Z Sexton
doi:10.1073/pnas.2105815118/-/DCSupplemental
The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the associated disease COVID-19, requires therapeutic interventions that can be rapidly identified and translated to clinical care. Traditional drug discovery methods have a >90% failure rate and can take 10 to 15 y from target identification to clinical use. In contrast, drug repurposing can significantly accelerate translation. We developed a quantitative high-throughput screen to identify efficacious agents against SARS-CoV-2. From a library of 1,425 US Food and Drug Administration (FDA)-approved compounds and clinical candidates, we identified 17 hits that inhibited SARS-CoV-2 infection and analyzed their antiviral activity across multiple cell lines, including lymph node carcinoma of the prostate (LNCaP) cells and a physiologically relevant model of alveolar epithelial type 2 cells (iAEC2s). Additionally, we found that inhibitors of the Ras/ Raf/MEK/ERK signaling pathway exacerbate SARS-CoV-2 infection in vitro. Notably, we discovered that lactoferrin, a glycoprotein found in secretory fluids including mammalian milk, inhibits SARS-CoV-2 infection in the nanomolar range in all cell models with multiple modes of action, including blockage of virus attachment to cellular heparan sulfate and enhancement of interferon responses. Given its safety profile, lactoferrin is a readily translatable therapeutic option for the management of COVID-19. SARS-CoV-2 | drug repurposing screening | COVID-19 | lactoferrin S evere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA betacoronavirus that emerged in Wuhan, China in November 2019 and rapidly developed into a global pandemic. The associated disease, COVID-19, manifests with an array of symptoms, ranging from flu-like illness and gastrointestinal distress (1, 2) to acute respiratory distress syndrome, heart arrhythmias, strokes, and death (3, 4). Recently, the US Food and Drug Administration (FDA) issued emergency approval of remdesivir, a nucleoside inhibitor prodrug developed for Ebola virus treatment (5). Although large-scale vaccination is ongoing worldwide, the need for safe, readily available antivirals is still a clinical priority. An antiviral compound that curbs infection and reduces COVID-19 symptoms would be highly useful to control local outbreaks or for home-based management, to protect immunocompromised patients for whom vaccination strategies are not suitable, and to slow the spread of variants of concern that could escape vaccine neutralization. Repurposing of FDA-approved drugs is a promising strategy for identifying rapidly deployable treatments for COVID-19. Benefits of repurposing include known safety profiles, robust supply
References
Avula, COVID-19 presenting as stroke, Brain Behav. Immun
Baeuerle, Huttner, Chlorate-a potent inhibitor of protein sulfation in intact cells, Biochem. Biophys. Res. Commun
Barrett, Treatment of moderate to severe coronavirus disease (COVID-19) in hospitalized patients
Berthold, KNIME-the Konstanz information miner, SIGKDD Explor
Blanco-Melo, Imbalanced host response to SARS-CoV-2 drives development of COVID-19, Cell
Bouhaddou, The global phosphorylation landscape of SARS-CoV-2 infection, Cell
Burock, Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: The NIKOLO trial, BMC Cancer
Cai, Liu, Zhang, Suppression of coronavirus replication by inhibition of the MEK signaling pathway, J. Virol
Chen, Li, Li, Yang, Hu, Hepatitis C virus increases free fatty acids absorption and promotes its replication via down-regulating GADD45α expression, Med. Sci. Monit
Conti, Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): Anti-inflammatory strategies, J. Biol. Regul. Homeost. Agents
Cutone, Lactoferrin prevents LPS-induced decrease of the iron exporter ferroportin in human monocytes/macrophages, Biometals
Dittmar, Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2, Cell Rep
Feng, Fenselau, Jacobson, Metabolism of clofazimine in leprosy patients, Drug Metab. Dispos
Ghahremanpour, Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2, ACS Med. Chem. Lett
Gu, Han, Wang, COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission, Gastroenterology
Gussow, Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses, Proc. Natl. Acad. Sci. U.S.A
Haffajee, Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias, Circulation
Han, Digestive symptoms in COVID-19 patients with mild disease severity: Clinical presentation, stool viral RNA testing, and outcomes, Am. J. Gastroenterol
Heiser, of human cells infected with SARS-CoV-2, doi:10.1101/2020.04.21.054387
Huang, Colaizzi, Bierman, Woestenborghs, Heykants, Pharmacokinetics and dose proportionality of domperidone in healthy volunteers, J. Clin. Pharmacol
Hung, Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An openlabel, randomised, phase 2 trial, Lancet
Hurley, Reconstructed single-cell fate trajectories define lineage plasticity windows during differentiation of human PSC-derived distal lung progenitors, Cell Stem Cell
Inc, Verapamil (package insert)
Jacob, Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells, Nat. Protocols
Jeon, Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs, Antimicrob. Agents Chemother
Kell, Heyden, Pretorius, The biology of lactoferrin, an iron-binding protein that can help defend against viruses and bacteria, Front. Immunol
Kochi, Tagliari, Forleo, Fassini, Tondo, Cardiac and arrhythmic complications in patients with COVID-19, J. Cardiovasc. Electrophysiol
Kuleshov, The COVID-19 drug and gene set library, Patterns (N Y)
Lagunas-Rangel, Chávez-Valencia, High IL-6/IFN-γ ratio could be associated with severe disease in COVID-19 patients, J. Med. Virol
Lancaster, Patel, Lennard, Lilleyman, 6-Thioguanine in children with acute lymphoblastic leukaemia: Influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations, Br. J. Clin. Pharmacol
Lang, Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans, PLoS One
Li, Chen, Kato, Gale, Lemon, Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes, J. Biol. Chem
Lin, Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection, Gut
Mariani, The combination of IFN β and TNF induces an antiviral and immunoregulatory program via non-canonical pathways involving STAT2 and IRF9, Cells
Mason, Pathogenesis of COVID-19 from a cell biology perspective, Eur. Respir. J
Mcquin, CellProfiler 3.0: Next-generation image processing for biology, PLoS Biol
Meyer, Quantifying drug combination synergy along potency and efficacy axes, Cell Syst
Mirabelli, Effect of lactoferrin treatment on iAEC2, doi:10.1073/pnas.2105815118
Mulangu, PALM Writing Group; PALM Consortium Study Team, A randomized, controlled trial of Ebola virus disease therapeutics, N. Engl. J. Med
Oda, Antiviral effects of bovine lactoferrin on human norovirus, Biochem. Cell Biol
Oprea, Drug repurposing from an academic perspective, Drug Discov. Today Ther. Strateg
Ou, Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV, Nat. Commun
Pardanani, TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations, Leukemia
Pharmaceuticals, Inc, Lomitapide (package insert)
Reghunathan, Expression profile of immune response genes in patients with severe acute respiratory syndrome, BMC Immunol
Riva, Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing, Nature
Roscow, Ganassin, Garver, Polinski, Z-FA-FMK demonstrates differential inhibition of aquatic orthoreovirus (PRV), aquareovirus (CSRV), and rhabdovirus (IHNV) replication, Virus Res
Siqueiros-Cendón, Immunomodulatory effects of lactoferrin, Acta Pharmacol. Sin
Stebbing, COVID-19: Combining antiviral and anti-inflammatory treatments, Lancet Infect. Dis
Stevens, Rudiger, Bednar, HoloViews: Building complex visualizations easily for reproducible science
Täubel, Single doses up to 800 mg of E-52862 do not prolong the QTc interval-A retrospective validation by pharmacokinetic-pharmacodynamic modelling of electrocardiography data utilising the effects of a meal on QTc to demonstrate ECG assay sensitivity, PLoS One
Wu, Yang, TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib, J. Microbiol. Immunol. Infect
Xiao, Evidence for gastrointestinal infection of SARS-CoV-2, Gastroenterology
Yin, Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir, Science
Yoneda, Secretoglobin superfamily protein SCGB3A2 alleviates house dust mite-induced allergic airway inflammation in mice, Int. Arch. Allergy Immunol
Yuan, Clofazimine broadly inhibits coronaviruses including SARS-CoV-2, Nature
Yuan, Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system, Pharmacol. Res
Zhang, The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China, Clin. Immunol
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit